February 10, 2020 / 1:15 PM / 16 days ago

BRIEF-Arbutus To Discontinue AB-452 And Pursue Development Of Next Generation Oral HBV RNA-destabilizer

Feb 10 (Reuters) - Arbutus Biopharma Corp:

* ARBUTUS ANNOUNCES DECISION TO DISCONTINUE AB-452 AND TO PURSUE DEVELOPMENT OF A NEXT GENERATION HBV SPECIFIC ORAL RNA-DESTABILIZER

* ARBUTUS BIOPHARMA CORP - ARBUTUS EXPECTS TO ANNOUNCE AB-729 PRELIMINARY PHASE 1A/1B DATA LATE Q12020

* ARBUTUS BIOPHARMA CORP - CONTINUE RESEARCH AND DEVELOPMENT OF A NEXT GENERATION ORAL HBV RNA-DESTABILIZER

* ARBUTUS BIOPHARMA CORP - REITERATED ITS EARLIER GUIDANCE FOR BOTH AB-729 AND AB-836

* ARBUTUS BIOPHARMA - FOR AB-836, ARBUTUS’ NEXT GENERATION CAPSID INHIBITOR, EXPECTS TO COMPLETE INVESTIGATIONAL NEW DRUG ENABLING STUDIES BY YEAR END

* ARBUTUS BIOPHARMA CORP - LOOK FORWARD TO ANNOUNCING OUR PRELIMINARY SAFETY AND EFFICACY DATA FOR AB-729 LATER THIS QUARTER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below